Skip to main content

Table 1 Comparison of Inclusion/Exclusion Criteria for the Per- Protocol (PP) and Modified Intention-to-Treat (MITT) Analyses

From: Robustness of the healthcare utilization results from the Rotavirus Efficacy and Safety Trial (REST) evaluating the human-bovine (WC3) reassortant pentavalent rotavirus vaccine (RV5)

Criteria for Comparison

PP Analysis

MITT Analysis

Infants Randomized but Not Vaccinateda

Excluded

Excluded

Infants without Follow-up

Excludes infants where the end of follow up occurs before 14 days after dose 3

Excludes infants where the end of follow up is the same day as the first vaccinationa

Infants classified as not-evaluable (Infants are classified as not-evaluable if they have one or more episodes not-evaluable for rotavirus and no episodes positive for rotavirus)

Episodes were classified as not-evaluable if the stool specimen was positive for wild-type rotavirus prior to 14 days after dose 3, if there was incomplete clinical and/or laboratory results, or the stool specimen was collected outside the 14 day range after symptom onset

Episodes were classified as not-evaluable if the clinical and/or laboratory results were incomplete or the stool specimen was collected outside the 14 day range after symptom onset

Infants with protocol violations

Excluded

Included

Serotypes

Overall analysis was limited to RVGE due to G1-G4 serotypes

Overall analysis included all RVGE regardless of serotype

  1. a There were no healthcare encounters on the day of the first vaccination.